Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- FOSTER CITY, Calif.–(BUSINESS WIRE) May 22, 2026 — Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevirtide-gmod) 8.5 mg for the treatment…
- Zug, Switzerland – May 22, 2026 – Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin Epiduo Acne Gel (Adapalene 0.1% and…
- Tokyo – (May 22, 2026) – Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic…
- May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood…
- Cary, N.C., May 18, 2026—Chiesi USA, Inc. (key-A-zee), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate; or…
- RALEIGH, N.C., May 18, 2026 /PRNewswire/ — Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the development of oncology, immunology and central nervous system (CNS)…
- FRIDAY, May 22, 2026 — For preschool-aged children presenting to the emergency department with moderate-to-severe acute wheezing, azithromycin does not lead to a reduction in the severity of wheezing-related symptoms, according to a study published…
- FRIDAY, May 22, 2026 — The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or who are…
- FRIDAY, May 22, 2026 — A history of atopic dermatitis (AD) is associated with an increased risk for retinal detachment (RD), according to a study published online May 18 in Ophthalmology Retina. Alexander T. Hong, from the Keck School of Medicine…
- FRIDAY, May 22, 2026 — The U.S. Food and Drug Administration has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early…
- FRIDAY, May 22, 2026 — Low-frequency contralesional repetitive transcranial magnetic stimulation (rTMS) is effective and safe for poststroke neurogenic overactive bladder (OAB), according to a study published online April 29 in Neurorehabilitation…
- FRIDAY, May 22, 2026 — Having a failed glucose challenge test (GCT) concentration without gestational diabetes mellitus (GDM) is associated with a higher risk for preterm birth and large for gestational age (LGA), according to a study published in…
Thông tin từ The Pharma Letter
- Important research news last week included Regeneron releasing disappointing Phase III data for its investigational drug fianlimab as a treatment for metastatic melanoma and positive results for Relay Therapeutics’ zovegalisib in vascular anomalies. Additionally, BioMarin released Phase III data on its hypochondroplasia drug Voxzogo. Also of note, SERB Pharmaceuticals acquired rights to Swedish firm Hansa […]
- The US Food and Drug Administration (FDA) has granted accelerated approval for Gilead Sciences’ Hepcludex (bulevirtide-gmod) 8.5mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the USA, and sending the firm’s shares up 3% to $134.36 by close on […]
- A consortium led by CVC Capital Partners has launched a 10.9 billion euros ($12.65 billion) bid to take Italian drugmaker Recordati (RECI: MI) private, in a deal that would tighten the buyout specialist’s control of the company and extend its bet on the rare disease market.
- AstraZeneca and Daiichi Sankyo have secured US approval for Datroway (datopotamab deruxtecan-dlnk) as a first-line treatment for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor therapy.
- California-based biotech Assembly Biosciences’ climbed 9.4% to $29.00 mid mid-morning, after it announced the pricing of an underwritten, registered offering of common stock and pre-funded warrants, expected to generate approximately $100 million in gross proceeds.
- The European Medicines Agency’s (EMA) human medicines committee (CHMP) today announced recommendations for medicines approval at its May 2026 meeting. These are passed on for European Commission final decisions, that usually come within two or three months.
Thông tin từ BioPharmaDive
- Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.
- High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
- Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
- The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
- Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.
- Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
Thông tin từ STAT News
- Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
- “There's a whole industry that seems to have sprung up”: Two experts on the people profiting from the rise of the perimenopause movement.
- The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable showdown with provider groups.
- Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
- Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
- Seed oil panic, how STIs spread, and more health news from Morning Rounds
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 22 May 2026; doi:10.1038/d41573-026-00087-5Incretin-based multi-agonist reverses obesity and diabetes
- Nature Reviews Drug Discovery, Published online: 20 May 2026; doi:10.1038/d41573-026-00084-8Nobel laureate Shinya Yamanaka discusses the therapeutic and drug discovery applications for induced pluripotent stem cells.
- Nature Reviews Drug Discovery, Published online: 20 May 2026; doi:10.1038/d41573-026-00085-7FDA approves first-in-class hypertension drug
- Nature Reviews Drug Discovery, Published online: 19 May 2026; doi:10.1038/s41573-026-01442-2Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and explains how recent mechanistic insights should broaden the scope and improve the safety and efficacy of immunotherapies based on […]
- Nature Reviews Drug Discovery, Published online: 18 May 2026; doi:10.1038/s41573-026-01449-9Autophagy has a highly complex and context-dependent role in cancer, challenging the development of autophagy-modulating strategies. This Review discusses the potential of targeting autophagy to counteract malignant transformation, prevent disease progression and enable anticancer immunosurveillance. Existing and emerging pharmacological strategies and the associated limitations are critically […]
- Nature Reviews Drug Discovery, Published online: 13 May 2026; doi:10.1038/d41573-026-00081-xTrends in the landscape of clinical trials of innovative drugs in China since 2015